nitroglycerin has been researched along with Fetal Growth Retardation in 10 studies
Nitroglycerin: A volatile vasodilator which relieves ANGINA PECTORIS by stimulating GUANYLATE CYCLASE and lowering cytosolic calcium. It is also sometimes used for TOCOLYSIS and explosives.
nitroglycerol : A nitrate ester that is glycerol in which nitro group(s) replace the hydrogen(s) attached to one or more of the hydroxy groups.
nitroglycerin : A nitroglycerol that is glycerol in which the hydrogen atoms of all three hydroxy groups are replaced by nitro groups. It acts as a prodrug, releasing nitric oxide to open blood vessels and so alleviate heart pain.
Fetal Growth Retardation: Failure of a FETUS to attain expected GROWTH.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the effects and possibility of nitroglycerin on Pregnancy induced hypertension (PIH) treatment." | 7.71 | [Therapeutic effects of nitroglycerin on pregnancy induced hypertension]. ( Chen, D; Xu, H, 2001) |
| "Seventeen patients with preeclampsia were treated with a nitroglycerin patch, 10 mg per 24 hours, for three consecutive days between 28 and 36 weeks' gestation." | 5.30 | Effects of transdermal nitroglycerin on impedance to flow in the uterine, umbilical, and fetal middle cerebral arteries in pregnancies complicated by preeclampsia and intrauterine growth retardation. ( Cacciatore, B; Halmesmäki, E; Kaaja, R; Teramo, K; Ylikorkala, O, 1998) |
| "Nitric oxide (NO) and adrenomedullin (AM) are both involved in the regulation of fetoplacental circulation in human pregnancy." | 5.10 | Maternal nitric oxide supplementation increases adrenomedullin concentrations in growth retarded fetuses. ( Cosmi, EV; Di Iorio, R; Di Netta, T; Gazzolo, D; Letizia, C; Marinoni, E, 2002) |
| "To evaluate the effects and possibility of nitroglycerin on Pregnancy induced hypertension (PIH) treatment." | 3.71 | [Therapeutic effects of nitroglycerin on pregnancy induced hypertension]. ( Chen, D; Xu, H, 2001) |
| "To our knowledge, this is the first time that a combination of aspirin and glyceryl trinitrate (GTN) has been used in the prophylaxis of preeclampsia and fetal growth retardation, and their use associated with not only Doppler screening of the uterine arteries but also regular Doppler follow-up of the fetal arterial and venous circulation." | 3.70 | A novel approach to the management of pregnancies complicated by uteroplacental insufficiency and previous stillbirth. ( Black, RS; Campbell, S; Lees, CC; Oyelese, KO, 1998) |
| " The present data suggest that the oxidative stress and reduced bioavailability of nitric oxide may contribute to attenuation of vasodilator responses to ACh and Ang II, and hyperreactivity to Ang II in the mesentery of preeclamptic rat, which may contribute to the increased peripheral vascular resistance and BP, as well as intrauterine growth restriction in L-NAME-induced PE." | 1.48 | Differential responses of mesenteric arterial bed to vasoactive substances in L-NAME-induced preeclampsia: Role of oxidative stress and endothelial dysfunction. ( Amaral, TAS; Carvalho, LCRM; Costa, CA; Moura, RS; Ognibene, DT; Resende, AC; Rocha, APM, 2018) |
| "Seventeen patients with preeclampsia were treated with a nitroglycerin patch, 10 mg per 24 hours, for three consecutive days between 28 and 36 weeks' gestation." | 1.30 | Effects of transdermal nitroglycerin on impedance to flow in the uterine, umbilical, and fetal middle cerebral arteries in pregnancies complicated by preeclampsia and intrauterine growth retardation. ( Cacciatore, B; Halmesmäki, E; Kaaja, R; Teramo, K; Ylikorkala, O, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (30.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pels, A | 1 |
| Ganzevoort, W | 1 |
| Kenny, LC | 1 |
| Baker, PN | 1 |
| von Dadelszen, P | 1 |
| Gluud, C | 1 |
| Kariya, CT | 1 |
| Leemhuis, AG | 1 |
| Groom, KM | 1 |
| Sharp, AN | 1 |
| Magee, LA | 1 |
| Jakobsen, JC | 1 |
| Mol, BWJ | 1 |
| Papageorghiou, AT | 1 |
| Robb, KP | 1 |
| Cotechini, T | 1 |
| Allaire, C | 1 |
| Sperou, A | 1 |
| Graham, CH | 1 |
| Amaral, TAS | 1 |
| Ognibene, DT | 1 |
| Carvalho, LCRM | 1 |
| Rocha, APM | 1 |
| Costa, CA | 1 |
| Moura, RS | 1 |
| Resende, AC | 1 |
| Trapani, A | 1 |
| Gonçalves, LF | 1 |
| Trapani, TF | 1 |
| Franco, MJ | 1 |
| Galluzzo, RN | 1 |
| Pires, MM | 1 |
| Di Iorio, R | 1 |
| Marinoni, E | 1 |
| Gazzolo, D | 1 |
| Letizia, C | 1 |
| Di Netta, T | 1 |
| Cosmi, EV | 1 |
| Halvorsen, CP | 1 |
| Andolf, E | 1 |
| Hu, J | 1 |
| Pilo, C | 1 |
| Winbladh, B | 1 |
| Norman, M | 1 |
| Cacciatore, B | 1 |
| Halmesmäki, E | 1 |
| Kaaja, R | 1 |
| Teramo, K | 1 |
| Ylikorkala, O | 1 |
| Oyelese, KO | 1 |
| Black, RS | 1 |
| Lees, CC | 1 |
| Campbell, S | 1 |
| Goodfellow, J | 1 |
| Bellamy, MF | 1 |
| Gorman, ST | 1 |
| Brownlee, M | 1 |
| Ramsey, MW | 1 |
| Lewis, MJ | 1 |
| Davies, DP | 1 |
| Henderson, AH | 1 |
| Xu, H | 2 |
| Chen, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Use of Sildenafil Citrate in Management of Mild Pre-eclampsia: A Randomized Controlled Trial[NCT03262961] | Phase 2/Phase 3 | 80 participants (Anticipated) | Interventional | 2016-09-15 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for nitroglycerin and Fetal Growth Retardation
| Article | Year |
|---|---|
Interventions affecting the nitric oxide pathway versus placebo or no therapy for fetal growth restriction in pregnancy.
Topics: Female; Fetal Death; Fetal Growth Retardation; Humans; Infant, Newborn; Nitric Oxide; Nitroglycerin; | 2023 |
2 trials available for nitroglycerin and Fetal Growth Retardation
| Article | Year |
|---|---|
Comparison between transdermal nitroglycerin and sildenafil citrate in intrauterine growth restriction: effects on uterine, umbilical and fetal middle cerebral artery pulsatility indices.
Topics: Administration, Cutaneous; Adult; Blood Flow Velocity; Double-Blind Method; Female; Fetal Growth Ret | 2016 |
Maternal nitric oxide supplementation increases adrenomedullin concentrations in growth retarded fetuses.
Topics: Administration, Cutaneous; Adrenomedullin; Adult; Double-Blind Method; Female; Fetal Growth Retardat | 2002 |
7 other studies available for nitroglycerin and Fetal Growth Retardation
| Article | Year |
|---|---|
Inflammation-induced fetal growth restriction in rats is associated with increased placental HIF-1α accumulation.
Topics: Animals; Disease Models, Animal; Female; Fetal Growth Retardation; Gene Expression Regulation; Gesta | 2017 |
Differential responses of mesenteric arterial bed to vasoactive substances in L-NAME-induced preeclampsia: Role of oxidative stress and endothelial dysfunction.
Topics: Acetylcholine; Angiotensin II; Animals; Arginine; Blood Pressure; Enzyme Inhibitors; Female; Fetal G | 2018 |
Discordant twin growth in utero and differences in blood pressure and endothelial function at 8 years of age.
Topics: Acetylcholine; Aorta, Abdominal; Blood Pressure; Brachial Artery; Carotid Arteries; Child; Diseases | 2006 |
Effects of transdermal nitroglycerin on impedance to flow in the uterine, umbilical, and fetal middle cerebral arteries in pregnancies complicated by preeclampsia and intrauterine growth retardation.
Topics: Administration, Cutaneous; Adult; Arteries; Blood Flow Velocity; Cerebral Arteries; Female; Fetal Gr | 1998 |
A novel approach to the management of pregnancies complicated by uteroplacental insufficiency and previous stillbirth.
Topics: Adult; Aspirin; Drug Therapy, Combination; Female; Fetal Death; Fetal Growth Retardation; Fetal Moni | 1998 |
Endothelial function is impaired in fit young adults of low birth weight.
Topics: Adult; Blood Pressure; Brachial Artery; Case-Control Studies; Endothelium, Vascular; Female; Fetal G | 1998 |
[Therapeutic effects of nitroglycerin on pregnancy induced hypertension].
Topics: Adult; Blood Pressure; Female; Fetal Growth Retardation; Humans; Hypertension; Nitroglycerin; Placen | 2001 |